Carl read the papersWhat it actually is
Crystagen is a synthetic tripeptide, Glu-Asp-Pro (EDP), from the Khavinson bioregulator family. The group reports EDP as one of the short peptides found inside Thymalin, the calf thymus extract they developed as a drug in the early 1980s.
It is sold as an immune peptide, usually pitched at people whose immunity has dropped off with age, which is also who the patent tested. Think of it as a single synthetic piece of the thymus extract rather than a new idea.
How it’s thought to work
- B-cell activation — In studies of the ageing spleen, reported to activate B-cells, but without boosting cell renewal.
- Gene expression — Proposed to bind DNA directly; docking models put EDP on the same DNA sequence as Vilon (KE).
- Lymphocyte growth — In one cell study, EDP (coded T-36) raised the spontaneous growth of normal lymphocytes at a tiny concentration (0.1 ng/ml).
- Chromatin — Reported to change how DNA is packed in lymphocytes from elderly people, in culture. The group's own write-ups disagree on which direction it goes.
What the research says
Very thin. The peer-reviewed record is a handful of cell and tissue studies from the Khavinson group. The human claim you will see repeated, immune markers normalised in 82% of elderly patients versus 56% of controls, comes from the group's own patent: 38 treated and 32 controls aged 62 to 83, all elderly people with long-term low-dose radiation exposure, 10 days of injections on top of standard treatment, no blinding or randomisation described. The group's 2021 review reports the same 82% as an oral result, so even the route is muddled. We found no registered trial, and the one forum thread we found was people planning to try it, not reporting results.
- Tripeptide Glu-Asp-Pro, reported as one of the short peptides inside the thymus extract Thymalin.
- Reported to activate B-cells in the ageing spleen without boosting cell renewal.
- Patent data: immune markers normalised in 82% of 38 elderly patients vs 56% of 32 controls.
- No registered human trial and no independent replication that we could find.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Community dose | Not established. The one forum thread we found was planning, not reporting |
| Figures quoted online | 10 to 20 mg a day as oral capsules for 10 to 20 days, on peptide database sites. No study is cited |
| Patent figures | Injected into muscle once daily for 10 days, at 10 mcg or 5 mg depending on how badly immunity was affected. A 500-fold jump, in a filing, not a validated dose |
| Cycle | Short courses, the standard pattern for this family |
| Carl's note | The online oral figures are 1,000 to 2,000 times the patent's 10 mcg injection. Different route, but nobody has worked out a human dose either way. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Age-related immune decline (how it is sold) | patent data only, no registered trial |
| Longevity courses | planned alongside Epithalon in one forum thread; no data on the combination |
| What it will not do | treat an infection, an immune disease or a low blood count |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
There is no established injected dose. The developer's patent used intramuscular injections once daily for 10 days, either 10 mcg or 5 mg depending on severity, in elderly patients who were also getting standard treatment. That is a filing, not a validated protocol. Online figures are for oral capsules at milligram amounts with no source. Anyone with genuinely weak immunity, frequent infections or a falling white cell count needs that investigated properly first. Reconstituted, keep it cold.
Stacks it appears in
- With Thymosin Alpha-1 — Both get filed under immune support, through quite different mechanisms. No study has combined them.
- With Epithalon — One forum thread plans an Epithalon plus Crystagen longevity cycle. No data on the combination.
Sources
- Chervyakova et al. 2014, Adv Gerontol: Immunoprotective activity of peptides in the ageing spleen
- Khavinson et al. 2021, Biology Bulletin Reviews: The use of Thymalin for immunocorrection (PMC8365293)
- Patent US8057810B2: Peptide substance revealing an immunogeroprotective effect (H-Glu-Asp-Pro-OH)
- Khavinson et al. 2022, Int J Mol Sci: table of named bioregulators
- Khavinson et al. 2016, Bull Exp Biol Med: Short peptides regulate gene expression (DNA docking)
- Voicekhovskaya et al. 2012, Bull Exp Biol Med: Bioregulatory tripeptides on rat skin cultures
- Khavinson et al. 2011, Bull Exp Biol Med: Effect of tripeptides on lymphoid and stem cells
- rapamycin.news: Epitalon and Crystagen longevity peptide cycle (forum thread)
- peptide-db.com Crystagen page (figures quoted online)
- ClinicalTrials.gov search: crystagen
- SAHPRA: Peptide Products - Public Information (May 2026)
- WADA 2026 Prohibited List (S0 non-approved substances)
